Achieve Life Sciences Inc SEC Filings

Achieve Life Sciences, Inc. (ACHV) reported an insider acquisition: Chief Operations Officer Craig Donnelly was granted a stock option on 10/01/2025 to purchase 50,000 shares of common stock at a $3.10 exercise price. The option vests with 1/4 of the award on the first anniversary of September 8, 2025 and then in substantially equal monthly installments over the following 36 months, subject to continued service. The Form 4 was signed by an attorney-in-fact on 10/03/2025. This filing documents a routine executive equity award that creates potential future dilution if exercised and ties the officer’s compensation to company share performance.

Mark K. Oki, Chief Financial Officer of Achieve Life Sciences, Inc. (ACHV), reported insider transactions on 09/18/2025. The filing shows settlement of 168,000 performance restricted stock units (PRSUs) into common stock, increasing his beneficial ownership to 178,000 shares immediately after settlement. Concurrently, the reporting person sold 50,060 shares in multiple transactions at a weighted average price of $2.92 per share (individual sale prices ranged from $2.83 to $3.02), reducing beneficial ownership to 127,940 shares. The PRSUs each represent a contingent right to one share and vest upon achievement of specified milestones; the related PRSUs list a date of 12/06/2028 in the filing. The sale is disclosed as made to satisfy income tax withholding and remittance obligations in connection with net settlement.

Richard Stewart, CEO and Director of Achieve Life Sciences (ACHV), reported settlement of performance restricted stock units and related share sales on 09/18/2025. He received 297,500 shares upon settlement of PRSUs and sold 129,501 shares in multiple transactions for a weighted average price of $2.92 per share to satisfy income tax withholding and remittance obligations. After these transactions the filing shows reported beneficial ownership positions including 358,376 shares (direct) and additional indirect holdings: 359 shares held by spouse and 882 held by Ricanto Limited, of which the reporting person is principal. Two tranches of PRSUs (140,000 and 157,500) remain listed with settlement tied to milestone vesting dates in 2028 and 2029.

Craig Donnelly, Chief Operations Officer of Achieve Life Sciences (ACHV), filed an initial Form 3 reporting direct ownership of 52,372 shares of common stock and two stock option awards. One option covers 25,000 shares exercisable beginning 03/14/2033 at $4.53; the other covers 22,500 shares exercisable beginning 01/22/2034 at $4.55. Vesting schedules for each grant are disclosed in the filing.

Mark K. Oki, Chief Financial Officer of Achieve Life Sciences, Inc. (ACHV), reported receipt of 168,000 performance restricted stock units (PRSUs) on 09/04/2025. The filing states these PRSUs were previously disclosed on December 9, 2024 and were earned after the Compensation Committee certified achievement of specified performance criteria. Each PRSU converts into one share of common stock at settlement. The reported award shows an exercise/settlement reference date of 12/06/2028 and a reported price of $0. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Oki on 09/08/2025.

Richard Stewart, a director and executive officer of Achieve Life Sciences, Inc. (ACHV), reported two awards of Performance Restricted Stock Units (PRSUs) on 09/04/2025. The filing shows acquisition of 140,000 PRSUs (linked to common stock) and 157,500 PRSUs, each representing a contingent right to one share at settlement. The PRSUs were previously reported as earned when performance targets were certified by the Compensation Committee. The awards list future settlement/exercise dates of 01/22/2028 and 01/13/2029 and show 0 shares beneficially owned following the transactions, indicating these remain contingent/subject to settlement terms.

Jerry Wan, identified as an officer (Principal Accounting Officer), reported transactions in Achieve Life Sciences, Inc. (ACHV) dated 09/04/2025. He received 34,100 shares of common stock upon settlement of performance restricted stock units (PRSUs) and sold 14,070 shares to satisfy tax withholding, at a weighted-average price of $2.77 per share (sales ranged from $2.68 to $2.88).

The filing shows PRSUs that were previously reported as earned by the Compensation Committee: one group of 24,500 PRSUs tied to milestone-based vesting and another group of 9,600 PRSUs with a vesting range of 0%–100% depending on future milestones. After these transactions the reporting person beneficially owned 46,764 shares.

Thomas B. King, a director of Achieve Life Sciences, Inc. (ACHV), settled performance-based equity and received 455,000 shares of common stock on September 4, 2025. These shares resulted from performance restricted stock units (PRSUs) that were previously reported as earned after the Compensation Committee certified achievement of certain performance criteria. To satisfy tax withholding obligations associated with the net settlement, 139,858 shares were sold at weighted-average prices between $2.68 and $2.88 per share, generating a reported sale price of $2.77 per share. After settlement and the withholding sale, the reporting person beneficially owned 315,142 shares directly.